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Abstract
Background and Aim: Pdt is an important palliative
option  for  patients  with  unresectable  extrahepatic
cholangiocarcinoma (cc). However, the results pub-
lished to date reported on studies with no more than 6
(mostly up to 4) Pdt procedures. Furthermore, the
clinical  experience  of  Pdt  in  combination  with
chemotherapy is limited. the purpose of this retro-
spective  analysis  was  to  evaluate  the  feasibility  and
safety of multiple (4 to 14) settings of Pdt, combined
with  biliary  drainage,  and  (in  some  cases)  with
chemotherapy.
Methods:  ten patients with unresectable extrahepatic
cc  were  treated  with  biliary  stenting  and  at  least  4
Pdt procedures in our department between 10/2005
and 08/2010. 
Results: ten patients (male/female = 5/5), mean age
68.8 years (range, 54 – 81 years) who received at least
4 Pdt procedures were analyzed. all patients under-
went  endoscopic  biliary  drainage.  nine  patients  re-
ceived metallic stents and one patient a plastic stent.
In  4  patients  (40%)  bilateral  metal  stenting  (Jostent
selfXﾮ) was performed. the mean number of Pdt
sessions was 7.9 ﾱ 3.9 (range: 4 – 14). Eight patients
had elevated bilirubin levels with a mean bilirubin at
admission of 9.9 ﾱ 11.3 mg/dl, which had decreased
to an average minimum of 1.2 ﾱ 0.9 mg/dl after 3
months. no severe toxicity was noted. two patients
received concomitant chemotherapy (gEMcIs as 1st
line, gEMoX plus cetuximab as 2nd line). the median
overall survival has not been reached, whereas the esti-
mated survival of all patients was 47.6 months, 95%
cI 25.9 – 48.1.
Conclusion: long-term Pdt in patients with extrahep-
atic cc is feasible and effective and is accompanied –
at least in this cohort- by a survival time of more than
2 years. 
Key words: cholangiocarcinoma, palliative care, photo-
dynamic therapy, chemotherapy 
Abbreviations: cc  =  cholangiocarcinoma,  Pdt  =
photodynamic therapy
IntRodUctIon
cholangiocarcinoma is the second most common pri-
mary hepatic malignancy, after hepatocellular carcino-
ma  [1].  between  50  and  90  percent  of  patients  with
cholangiocarcinoma  present  with  locally  unresectable
disease and their prognosis is poor. Relief of progres-
sive biliary obstruction is one of the goals of palliative
therapy. Photodynamic therapy (Pdt) is an important
palliative  option  for  patients  with  unresectable  extra-
hepatic cholangiocarcinoma [2]. It combines a photo-
sensitizer  such  as  Photofrinﾮ with  subsequent  endo-
scopic application of red laser light (630 nm) to destroy
cancer  cells.  the  interaction  between  photosensitizer,
light and oxygen causes tumor cell death, presumably
by the generation of free oxygen radicals [3]. Improve-
ments in survival time, biliary drainage and quality of
life in patients with advanced extrahepatic cholangio-
carcinoma have been reported in several uncontrolled
studies  and  been  confirmed  in  two  randomised  con-
trolled trials [4-13]. Pdt seems to be much better toler-
ated than chemotherapy and radiotherapy and can be
repeated without leading to an accumulation of adverse
events. However, the studies published so far dealt with
a rather low number of Pdt procedures (1 to 6, mostly
1 to 4). Furthermore, the clinical experience of Pdt in
combination with chemotherapy is limited.
the purpose of the present retrospective analysis
was to evaluate the feasibility and safety of multiple (4
to  14)  settings  of  photodynamic  therapy,  combined
with  biliary  drainage  and  (in  some  cases)  with
chemotherapy.
PatIEnts and MEtHods
PatIEnts
ten patients with unresectable extrahepatic cholangio-
carcinoma treated with at least 4 Pdt procedures in
the department of Internal Medicine of the Universi-
ty Hospital bonn between 10/2005 and 08/2010 were
retrospectively analyzed (76 patients were treated with
Pdt  in  this  period).  the  disease  diagnosis  was  ob-
tained by intraoperative biopsy in 2 patients, by endo-
scopic biopsy or brushing in 4 patients. In 4 (40%) pa-
tients the diagnosis was based on data from computed
tomography  (ct)  scan,  magnetic  resonance  imaging
(MRI),  abdominal  ultrasound,  or  endoscopic  retro-
grade  cholangiopancreatography  (ERcP),  and  sup-
ported by growth of the tumor lesion during follow-
up. Metastatic disease was present in 3 patients at the
time of diagnosis (lymph nodes n = 2, peritoneal car-
cinomatosis n = 1).
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all 10 patients underwent endoscopic biliary drainage.
three  patients  required  transient  external  drainage
(percutaneous drainage) and one patient received dur-
ing  the  disease  a  combination  of  internal  stenting 
and  external-internal  yamakawa-type  endoprosthesis
(Pflug  beil, Zoem  ding, germany) because of technical
failure of the endoscopic way. the median number of
endoscopic  procedures  per  patient  (excluding  Pdt
procedures) was 3.
Endoscopic procedures were performed under anal-
getic  sedation  with  midazolam  and/or  propofol  and
pethidin.  9  patients  (90%)  received  metallic  stents,
whereas one patient had plastic stent, which was regu-
larly replaced. In 4 patients (40%) bilateral metal stent-
ing  (Jostent  selfXﾮ,  abbott  vascular  deviced,  Red-
wood city, ca, Usa) was performed as described pre-
viously [16]. In 3 of them, bilateral stenting was per-
formed at one endoscopic session and in one patient
during  two  endoscopic  procedures.  one  patient  re-
ceived 44mm stents and one patient 68mm stents bilat-
erally. In 2 patients a 44mm stent was placed at the
right and a 68mm prothesis was placed at the left he-
patic  duct.  three  patients  received  unilateral  metal
stenting: in 2 patients 68mm Jostent selfXﾮ was placed
at  the  right  and  in  1  patient  a  44mm  prothesis  was
placed at the left hepatic duct. one patient who had
cholangiocarcinoma of the common bile duct received
a  bare  biliary  wallstentﾮ (boston  scientific,  natick,
Ma, Usa), followed in a course of the disease by a
placement of a covered 68mm wallstent. one patient
received an uncovered wallstentﾮ at the right bile duct.
oral ciprofloxacin therapy 500 mg twice daily was
started before ERcP and continued for 3 days. when
there  was  evidence  of  cholangitis,  bile  was  sent  for
culture and sensitivity testing.
PHotodynaMIc tHERaPy
Pdt was performed as described previously [8]. Pa-
tients received intravenous Photofrin (axcan Pharma
Inc.,  Mount-saint-Hilaire,  canada)  at  a  dose  of  2
mg/kg  bodyweight  48  hours  before  laser  activation.
one  patient  received  after  7th Pdt-procedure
Photofrin at the reduced dose of 1 mg/kg bodyweight
because of the phototoxic skin reaction on the hands.
Pdt was performed 48 hours after sensitization with
630  nm  light  (ceralas  Pdt  630  diode  laser;  cer-
amoptec gmbH, bonn, germany) at a light dose of
200 J/cm length of stenosis (Fig. 1).
cHEMotHERaPy
In 2 patients the photodynamic therapy was combined
with chemotherapy. one patient received chemothera-
py with gemcitabine and cisplatin (12 cycles). the sec-
ond patient received combination therapy with gem  -
citabine  and  cisplatin  (4  cycles)  as  1st line  therapy,
which was changed at tumor progress to gemcitabine-
oxaliplatin (gEMoX) plus cetuximab as 2nd line ther-
apy (6 cycles) with subsequent change to gemcitane-
cisplatin (gEMcIs) plus cetuximab because of oxali-
platin-induced polyneuropathy. the time intervals of 2
weeks  were  kept  between  the  Pdt  procedures  and
chemotherapy cycles in order to avoid cumulative ad-
verse events. 
statIstIcal analysIs
Results are expressed as arithmetic mean ﾱ sd. statis-
tical analysis was performed using the statview 5.0™
(version for windows; sas Institute Inc., cary, nc,
Usa)  and  sPss  software  (sPss  Inc.,  chicago,  Il,
Usa). the Kaplan-Meier method was used to estimate
overall survival outcomes. overall survival was calcu-
lated from the first ERcP to the date of death or last
follow-up.
REsUlts
PatIEnt cHaRactERIstIcs
ten patients (male/female = 5/5), mean age 68.8 years
(range, 54 – 81 years) which received at least 4 Pdt
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Fig. 1. 14th elective Pdt in a 80-year-
oldpatientsuffering from cholangiocar-
cinoma  bismuth  stage  Iv.  bilaterally
placement  of  Jostent  selfX  was  per-
formed 2008 at the time of initial dia  -
gnosis.
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hilar cholangiocarcinoma at stage bismuth Iv and one
patient had cholangiocarcinoma of distal common bile
duct. the clinical characteristics of this retrospective
study population are summarized in table 1. Metas-
tases  in  regional  lymph  nodes  were  observed  in  tu-
mors of 2 (20%) patients whereas 1 patient had peri-
toneal  carcinomatosis,  confirmed  by  intraoperative
biopsy.
saFEty
the first Pdt was performed after a mean time of
39.6 ﾱ 22.9 days following the first ERcP procedure.
the median number of Pdt sessions was 6/patient
(range: 4 – 14). In 4 patients the Pdt was performed
as soon as signs of tumor progression occurred and in
6 patients the Pdt was performed at regular intervals
of 1-2 months, even in the absence of tumor progres-
sion signs. the procedure was performed endoscopi-
cally in all patients. the primary adverse event after in-
tervention was cholangitis in 2 patients (20%), which
was treated with antibiotics alone. In one patient, we
performed subsequent Pdt procedures without using
a biliary contrast with no cholangitis episodes there-
after.  one  patient  experienced  skin  phototoxicity
world Health organization grade I after the seventh
Pdt procedure. He was managed with topical therapy,
no hospital readmission was required. we continued
the Pdt with 50% dosis reduction of Photofrin and
observed no phototoxicity reactions after subsequent
procedures. no other complications related specifical-
ly to Pdt were noted.
bIlIaRy dEcoMPREssIon
two patients showed no hyperbilirubinemia at admis-
sion in our hospital due to primary intervention by the
referring centre using plastic stents. Eight patients had
elevated bilirubin levels with the mean bilirubin at ad-
mission of 9.9 ﾱ 11.3 mg/dl. In this group the biliru-
bin level was successfully decreased: after 3 months a
greater than 50% reduction was noted in 6 out of 8
(75%) patients and the mean bilirubin level was 1.2 ﾱ
0.9 mg/dl.
the mean number of cholangitis episodes was 3.3
ﾱ 3.4 per patient in the whole cohort, which was de-
fined as fever (>38ﾰc) and right upper quadrant ab-
dominal pain. no cholecystitis or liver abscesses were
seen. one patient developed empyema of gall bladder,
requiring  cholecystectomy,  but  this  complication  oc-
curred 5 months after Pdt and is rather not related to
photodynamic  therapy  or  ERcP.  one  patient  devel-
oped  a  chronic  cholangitis  caused  by  Pseudomonas
aeruginosa, treated by a long-term administration of
ertapenem.
sURvIval
the  mean  follow-up  time  was  27.98  ﾱ  11  months.
Four patients died during the follow-up because of tu-
mor progression. the median overall survival has not
been reached, the estimated survival (sPss) was 47.6
months, 95% cI 25.9 – 48.1 months. the survival data
for all patients are shown in table 1.
tumor  progression  (growth  of  the  hilar  lesion,
peritoneal  carcinomatosis,  liver  and  lymph  node
metastases) in the last imaging session was noted in 4
of the 7 patients who are still alive.
dIscUssIon
Most patients with cholangiocarcinoma are diagnosed
at an advanced stage, when treatment is essentially pal-
liative. Improvements in biliary drainage, survival time
and quality of life in patients with advanced cc have
been reported in several uncontrolled studies and been
confirmed in two randomised controlled trials [4-15].
In the first Rct of 39 patients with large (>3 cm) hi-
lar tumors, ortner et al. demonstrated superior medi-
an survival (493 vs 98 days, p<0.0001), improved bil-
iary drainage and improvement of Karnofski perfor-
mance status in the Pdt group [9]. this study includ-
ed only patients with a bilirubin decrease of less than
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Table 1. Patient characteristics.
Patient Gender Age at  Tumor  Number of  Chemo- Survival  Status Tumor 
diagnosis site PDT  therapy (months) progression
procedures
1F71 Hilum 5 no 40.4 alive yes
2 M 78 Hilum 14 no 25.0 alive yes
3M 60 Hilum 10 no 19,9 dead -
4F81 Hilum 6 no 9.3 dead -
5F63 dHc 5 yes 17.5 alive no
6F66 Hilum 4 no 47.6 dead -
7M 67 Hilum 13 no 25.1 alive yes
8F54 Hilum 6 yes 12.6 alive yes
9M 66 Hilum 12 no 31.0 alive no
10 M 79 Hilum 4 no 30.9 dead -
F, female; M, male. 
3) Höblinger_Umbruchvorlage  04.08.11  15:53  Seite 39350% after biliary stenting and was therefore criticized
on grounds of potential bias. the second prospective
randomised trial included 32 unselected nonresectable
patients,  especially  those  with  successful  biliary
drainage, and confirmed the survival advantage in the
Pdt group (630 vs 210 days, p = 0.019) [12]. Perfo-
mance status did not improve, but remained constant
during the whole observation period. witzigmann et
al. have analyzed prospectively treatment and outcome
data  of  184  patients  with  hilar  cholangiocarcinoma,
treated with either surgery, stenting alone or Pdt plus
stenting.  this  study  showed  similar  survival  time  of
patients treated with Pdt to that of patients with in-
complete R1-R2 resection (366 days), but with a con-
siderably lower rate of complications [13].
as shown in table 2, most clinical studies on Pdt
for  cholangiocarcinoma  performed  a  rather  limited
(mostly 1 to 4) number of Pdt procedures. this is
the first clinical report of a long-term repeat photody-
namic therapy (4 – 14 procedures) in patients with in-
operable cc. Furthermore, two patients were success-
fully  treated  with  the  combination  of  Pdt  and
chemotherapy. compared to the previously reported
median survival times of about 14-20 months in the
most studies and the median survival of 16.5 months
in our own recently published cohort of patients treat-
ed with 1 to 4 Pdt procedures [17], the patients of
this study showed an impressive estimated survival of
47.6  months,  despite  having  locally  advanced  or
metastatic disease. tumor destruction by Pdt is not
only a result of apoptosis or necrosis of cancer cells
via generation of reactive oxygen species. Pdt also
induces secondary events including microvascular dis-
ruption and local active inflammation. Moreover, al-
though Pdt was originally considered a local treat-
ment, several studies have shown that Pdt leads to
enhancement  of  anti-tumor  immunity  [14].  Further
evaluation whether enhanced immune responses con-
tribute to improved local or systemic tumor control
requires well-designed clinical trials with large enough
patient populations to provide statistical relevance and
correlative immunologic endpoints. 
Recently, factors associated with increased survival
after Pdt were analyzed in a retrospective study of 25
patients with unresectable cc treated with Pdt in ad-
dition to biliary decompression [15]. the presence of a
visible mass on imaging studies, a lower serum albumin
level and increasing time between diagnosis and Pdt
predicted a poorer survival rate. this study indicates
the importance of early treatment with Pdt after diag-
nosis of unresectable cc. In our cohort the first Pdt
was performed after a mean time of 39.6 [14-84] days
following the first ERcP procedure. this time interval
is longer than in most previous published studies.
the major adverse effects of Pdt include photo-
sensitivity caused by retention of photosensitizers by
the skin (in case of Photofrinﾮ, phototoxicity of 4-6
weeks) and local complications such as cholangitis, bil-
ioma, liver abscess and hemobilia. two patients in our
study developed cholangitis after Pdt which required
prolonged  hospitalization  and  was  mainly  associated
with the endoscopic procedure. we did not observe
any severe phototoxicity (grade III) or other adverse
events directly related to Pdt.
two patients in our study received combination of
Pdt with systemic chemotherapy, which was well tol-
erated without cumulation of adverse effects. this is
in concordance with the report from Fuks and with
our own recently published results.
In conclusion, our present study demonstrates that
long-term repeat photodynamic therapy with multiple
Pdt procedures is feasible and safe in patients with
unresectable  extrahepatic  cholangiocarcinoma.  the
more  aggressive  treatment  strategy  combining  Pdt
with systemic chemotherapy is well tolerated and can
be safely performed in selected patients. Further stud-
ies  are  necessary  to  evaluate  the  effect  of  Pdt  in
combination  with  chemotherapy  on  survival,  which
may become a gold standard of care for palliation of
cholangiocarcinoma.
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Table 2. studies on photodynamic therapy in unresectable cholangiocarcinoma.
Study Year Study type Number  Mean PDT  Median  Adverse events: 
of patients sessions (range) survival (months) phototoxicity, cholangitis
ortner  1998 single arm 9 1.5 (1-2) 14.6 1 (11%), 0 (0%)
berr 2000 single arm 23 3 (1-5) 11.1 3 (13%), 8 (35%)
Zoepf 2001 single arm 8 1-2 4 0, 2 (25%)
Rumalla 2001 single arm  6 2.3 (1-2) >6 2 (33%), 2 (33%)
dumoulin 2003 single arm 24 1-2 9.9 2 (8%), 5 (21%)
ortner 2003 Randomized 39 2.4 (1-5) 16.4 2 (10%), 5 (25%)
ortner 2003 nonrandomized 31 1.5 (1-4) 14.2 3 (10%), 6 (19%)
Harewood 2005 single arm  8 2 (1-5) 9.2 2 (25%), 2 (25%)
shim 2005 single arm  24 1-4 18.6 1 (4%) liver abscess
Zoepf 2005 Randomized 32 1-3 20.6 0, 4 (25%)
witzigmann 2006 single arm  68 2 (1-6) 12 8 (12%), 38 (56%)
Prasad 2007 single arm 25 1.6 (1-4) 13.4 1 (4%), 2 (8%)
Fuks 2009 single arm 14 2 (1-4) 13.8 2 (14%), 8 (57%)
this study 2010 single arm  10 8 (4-14) >25 1 (10%), 2 (20%)
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